Relationship with Volition RX

Our work with Volition RX, quoted on the New York Stock Exchange, demonstrates our ability to partner with companies that need help with investor relations and to promote their work at the cutting edge of science and technology.

From humble beginnings, when we interviewed Volition’s President & CEO, Cameron Reynolds, about the company’s financial results, we are delighted to report that we are now working with this fast growing organisation on a variety of levels.

Volition is a multi-national company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present. Volition’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition’s research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Good Call Media is now helping to promote many aspects of Volition’s groundbreaking work in different areas of the world. As well as regularly featuring the company’s financial performance, we were invited to cover the opening of Volition’s state of the art new laboratories in Namur, Belgium – an investment which is helping to take the company to the next level as it rolls out its blood-based cancer tests to new areas and into new disciplines.

The investment will enable the Company to increase capacity to carry out clinical trials and to expand its scientific team, thereby expediting the large number of trials underway. The new custom-designed facility comprises 9,000 square feet of office space and 10,000 square feet of high quality, purpose-built laboratory space. The facility is located in the Crealys Science Park, Isnes in the Wallonia region of Belgium, an area popular with other leading biotech and pharmaceutical companies.

Recently we also highlighted Volition’s involvement in a number of high level and events and conferences in the Asian zone where the company is active. This included an interview with Dr. Jasmine Kway, VP of Volition Asia who highlighted the main aspects of Volition’s work in the region. “Asia is a very important market for Volition and we have made significant progress in the region since January of this year,” said Dr. Kway.” Our meetings at APDW and TDDW will give us excellent opportunities to further our conversations and formalize our engagements with key individuals in the Asia Pacific region.”

In October 2017 we also travelled to the company’s laboratories in Namur, Belgium, to record a comprehensive update entitled ‘The Science Behind Our Work’, featuring Dr. Jake Micallef, the Chief Scientific Officer of Volition. He gave a detailed explanation of the company’s progress in developing its blood-based tests and also highlighted the possibility of Volition’s engagement in the diagnosis of other types of cancer. The video is available through Volition’s own video gallery.

Volition’s goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. Volition’s research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide. The Company recently announced its strategy for a new range of Clinical Research Use Only (RUO) kits based on its proprietary Nucleosomics™ technology and the receipt of an order of RUO kits from a large multinational pharmaceutical company.

Chief Executive Officer of Volition, Cameron Reynolds, commented, “This is a very important milestone for Volition as it represents our first revenue from the Nu.Q™ platform. The RUO kits could be used to develop a companion diagnostic to a pharmaceutical company’s therapeutic product, so could represent an additional potential revenue stream beyond the commercialization of our blood-based cancer tests on the same platform of assays. After the initial sale of the RUO kits, a significant licensing arrangement is possible if the assays become a crucial component of another company’s product.”